3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
52
Lung Neoplasms
28
Ovarian Neoplasms
12
Triple Negative Breast Neoplasms
11
Small Cell Lung Carcinoma
11
Endometrial Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
10
Neoplasms
10
Fallopian Tube Neoplasms
10
Breast Neoplasms
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Neoplasm Metastasis
7
Colorectal Neoplasms
5
Adenocarcinoma of Lung
5
Carcinoma
4
Pancreatic Neoplasms
3
Oropharyngeal Neoplasms
3
Lung Diseases
3
Esophageal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Thoracic Neoplasms
2
Sarcoma
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Pathologic Complete Response
2
Non-squamous Non-small Cell Lung Cancer
2
Neoplasms by Site
2
Interventions
durvalumab
2
abemaciclib
2
Pemetrexed
2
Fulvestrant
2
Cisplatin
2
Carboplatin
2
ribociclib
1
repotrectinib
1
pembrolizumab
1
palbociclib
1
exemestane
1
elacestrant
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
STX-478
1
RAD1901
1
Nivolumab
1
Metformin
1
Letrozole
1
Immunotherapy
1
Imlunestrant
1
Drug Therapy
1
Docetaxel
1
Bevacizumab
1
Anastrozole
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Carboplatin
×
30 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled
NCT07279935
2026-06-01
REVIVE
AstraZeneca
Phase 4
Recruiting
100 enrolled